Prosecution Insights
Prosecution Insights
Technology areas: Biotechnology & Pharmaceuticals • Chemistry & Materials
13 pending office actions • 11 art units • 13 examiners • 0 of 13 (0%) have an AI response strategy ready • 4 patents granted in the last 365 days
The University of Queensland is managing 14 pending office actions within the Chemistry & Materials technology area. This portfolio is diversified, involving 14 distinct examiners and 12 distinct art units. The fact that the company has 14 pending office actions assigned to 14 distinct examiners indicates a lack of examiner overlap, which is notable for a portfolio of this size. This distribution suggests that each application is being treated as a unique technical entity by the patent office, potentially increasing the complexity of managing consistent prosecution across the 12 distinct art units involved.
KELLY, ROBERT M is the busiest examiner, responsible for 1 busiest examiner pending action. Given that there are 14 pending office actions and 14 distinct examiners, the workload is distributed, with no individual examiner handling more than 1 pending case. This ratio between the 14 pending office actions and 14 distinct examiners means that the university's success is not tied to any specific individual's examination style. Instead, the outcomes will depend on the university's ability to navigate the requirements of many different examiners across the Chemistry & Materials field.
Based on the USPTO statutory response window for each pending office action. 3 of the docket's apps have a known mailing date; the rest are excluded from the tile counts.
Every pending office action with a known statutory deadline, placed on a days-until-due axis. Dots left of Today are overdue; the further right, the more runway. Cases that share a deadline window stack vertically. 3 of the docket's apps have a known mailing date.
Difficulty is derived from the rejection statutes on the most recent pending office action. §101-driven and multi-statute cases are graded Hard; §112-only and obviousness-type double-patenting cases are graded Easy; everything else is Medium. "Unknown" means we have not yet parsed a statute for that office action.
| Bucket | Cases |
|---|---|
| §101 only | 1 (8%) |
| §101 + other | 3 (23%) |
| §103 only | 1 (8%) |
| §102 only | 2 (15%) |
| §112 only | 2 (15%) |
| Multi-statute (no §101) | 4 (31%) |
How the docket's pending cases split across USPTO tech-center bands.
Manual office-action response work runs about 10 hours per case. The time-saved bands below show what IP Author's prosecution pipeline typically delivers — a conservative 20% on the low end, 35% in the middle, 50% on the high end.
| Examiner | Apps on this docket | Allow rate | Interview lift |
|---|---|---|---|
| KELLY, ROBERT M | 1 | 74.1% | +24.6% |
| MAUPIN, HUGH H | 1 | 87.4% | +6.4% |
| MCGUIRK, JOHN SCHUYLER | 1 | 78.0% | +48.4% |
| WECKER, JENNIFER | 1 | 71.0% | +36.1% |
| CHACKO DAVIS, DABORAH | 1 | 72.1% | +20.6% |
| LI, AIQUN | 1 | 63.8% | +23.1% |
| LANGEL, WAYNE A | 1 | 78.4% | +23.2% |
| BOHATY, ANDREW K | 1 | 65.6% | +23.2% |
| ROONEY, NORA MAUREEN | 1 | 60.3% | +23.6% |
| MERCIER, MELISSA S | 1 | 72.1% | +5.8% |
Multi-statute / §101-driven matters, or cases in front of an examiner with an allow rate under 30%. The top 8 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 17286220 | A METHOD AND APPARATUS FOR DIAGNOSIS OF MALADIES FROM PATIENT SOUNDS | MELHUS, BENJAMIN S | 308d overdue |
| 18252510 | TREATMENT OF BAUXITE RESIDUE | LANGEL, WAYNE A | 26d |
| 18872451 | A Cell Surface Marker Signature for Arrhythmogenic Pluripotent Stem Cell-Derived Cardiomyocytes | KELLY, ROBERT M | — |
| 18914388 | DETECTION METHOD | MAUPIN, HUGH H | — |
| 18562197 | RAPID MEASUREMENT OF COAL OXIDATION | MCGUIRK, JOHN SCHUYLER | — |
| 18254569 | GRAPHENE PROCESSING TECHNIQUE | LI, AIQUN | — |
| 18247963 | TRIPLET QUENCHING | BOHATY, ANDREW K | — |
| 18023274 | SOL-GEL COMPOSITION | MERCIER, MELISSA S | — |
Cases in front of an examiner whose interview lift is 10 percentage points or more — i.e. interviewed cases historically resolve more favorably than non-interviewed ones. The top 8 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18252510 | TREATMENT OF BAUXITE RESIDUE | LANGEL, WAYNE A | 26d |
| 18872451 | A Cell Surface Marker Signature for Arrhythmogenic Pluripotent Stem Cell-Derived Cardiomyocytes | KELLY, ROBERT M | — |
| 18562197 | RAPID MEASUREMENT OF COAL OXIDATION | MCGUIRK, JOHN SCHUYLER | — |
| 18552340 | METHOD OF DETECTION | WECKER, JENNIFER | — |
| 18350480 | Wafer Bow Mitigation | CHACKO DAVIS, DABORAH | — |
| 18254569 | GRAPHENE PROCESSING TECHNIQUE | LI, AIQUN | — |
| 18247963 | TRIPLET QUENCHING | BOHATY, ANDREW K | — |
| 18029954 | CLEC9A antibodies | ROONEY, NORA MAUREEN | — |
| Art Unit | Apps |
|---|---|
| 1638 | 1 |
| 1798 | 1 |
| 1796 | 1 |
| 1737 | 1 |
| 1766 | 1 |
| 1736 | 1 |
| 1641 | 1 |
| 1615 | 1 |
| 1646 | 1 |
| 3797 | 1 |
| App # | Title | Examiner | Art Unit | Statutes | Status | Due in | AI | Filed |
|---|---|---|---|---|---|---|---|---|
| 18872451 | A Cell Surface Marker Signature for Arrhythmogenic Pluripotent Stem Cell-Derived Cardiomyocytes | KELLY, ROBERT M | 1638 | §101§102§112 | Non-Final OA | — | Pending | Dec 06, 2024 |
| 18914388 | DETECTION METHOD | MAUPIN, HUGH H | — | §102§103 | Non-Final OA | — | Pending | Oct 14, 2024 |
| 18562197 | RAPID MEASUREMENT OF COAL OXIDATION | MCGUIRK, JOHN SCHUYLER | 1798 | §101§102§103 | Non-Final OA | — | Pending | Nov 17, 2023 |
| 18552340 | METHOD OF DETECTION | WECKER, JENNIFER | 1796 | §102 | Non-Final OA | — | Pending | Sep 25, 2023 |
| 18350480 | Wafer Bow Mitigation | CHACKO DAVIS, DABORAH | 1737 | §103 | Non-Final OA | — | Pending | Jul 11, 2023 |
| 18254569 | GRAPHENE PROCESSING TECHNIQUE | LI, AIQUN | 1766 | §102§112 | Non-Final OA | — | Pending | May 25, 2023 |
| 18252510 | TREATMENT OF BAUXITE RESIDUE | LANGEL, WAYNE A | 1736 | §103§112 | Non-Final OA | 26d | Pending | May 10, 2023 |
| 18247963 | TRIPLET QUENCHING | BOHATY, ANDREW K | — | §101§102§103 | Non-Final OA | — | Pending | Apr 05, 2023 |
| 18029954 | CLEC9A antibodies | ROONEY, NORA MAUREEN | 1641 | §112 | Non-Final OA | — | Pending | Apr 03, 2023 |
| 18023274 | SOL-GEL COMPOSITION | MERCIER, MELISSA S | 1615 | §102§103§112 | Non-Final OA | — | Pending | Feb 24, 2023 |
| 17774796 | BINDING PROTEINS TO CUB DOMAIN-CONTAINING PROTEIN (CDCP1) | SANG, HONG | 1646 | §102 | Non-Final OA | — | Pending | May 05, 2022 |
| 17433949 | ACOUSTIC ENERGY TREATMENT | MOHAMMED, SHAHDEEP | 3797 | §112 | Non-Final OA | 30d overdue | Pending | Aug 25, 2021 |
| 17286220 | A METHOD AND APPARATUS FOR DIAGNOSIS OF MALADIES FROM PATIENT SOUNDS | MELHUS, BENJAMIN S | 3791 | §101 | Final Rejection | 308d overdue | Pending | Apr 16, 2021 |
IP Author helps IP teams respond to office actions faster with AI-generated responses, examiner analytics, and prosecution intelligence.
Start Free Trial